Equivariant Shape-Conditioned Generation of 3D Molecules for Ligand-Based Drug DesignDownload PDF

Published: 01 Feb 2023, Last Modified: 13 Apr 2023ICLR 2023 posterReaders: Everyone
Keywords: molecules, equivariance, generation
Abstract: Shape-based virtual screening is widely used in ligand-based drug design to search chemical libraries for molecules with similar 3D shapes yet novel 2D graph structures compared to known ligands. 3D deep generative models can potentially automate this exploration of shape-conditioned 3D chemical space; however, no existing models can reliably generate geometrically realistic drug-like molecules in conformations with a specific shape. We introduce a new multimodal 3D generative model that enables shape-conditioned 3D molecular design by equivariantly encoding molecular shape and variationally encoding chemical identity. We ensure local geometric and chemical validity of generated molecules by using autoregressive fragment-based generation with heuristic bonding geometries, allowing the model to prioritize the scoring of rotatable bonds to best align the growing conformation to the target shape. We evaluate our 3D generative model in tasks relevant to drug design including shape-conditioned generation of chemically diverse molecular structures and shape-constrained molecular property optimization, demonstrating its utility over virtual screening of enumerated libraries.
Anonymous Url: I certify that there is no URL (e.g., github page) that could be used to find authors’ identity.
No Acknowledgement Section: I certify that there is no acknowledgement section in this submission for double blind review.
Code Of Ethics: I acknowledge that I and all co-authors of this work have read and commit to adhering to the ICLR Code of Ethics
Submission Guidelines: Yes
Please Choose The Closest Area That Your Submission Falls Into: Machine Learning for Sciences (eg biology, physics, health sciences, social sciences, climate/sustainability )
TL;DR: We develop a shape-conditioned 3D generative model for ligand-based drug design
Supplementary Material: zip
21 Replies